Pharmaceutical company conducts self-contained generator power supply drill
Release time:
2020-08-14
Pharmaceutical Company Conducted Power Supply Exercise for Self-provided Generators
News 3# July 31 Afternoon, Jinhua Pharmaceutical Company's self-provided diesel generator set started operation to generate electricity, cut off the mains electricity, converted to generator power supply and sent it to the electrical equipment of the storage department, and conducted an "actual combat exercise".
Drug Business Quality Management Standard (GSP ) has strict requirements on the storage temperature and humidity of drug warehouses. Normal temperature warehouses, cool warehouses, cold warehouses, etc. all have corresponding temperature and humidity control, and are connected to the provincial drug administration department for real-time monitoring. For this reason, in 2014 , the pharmaceutical company purchased a 200 kW diesel generator set to ensure emergency power supply for the operation of refrigeration equipment in the pharmaceutical warehouse in case of sudden power failure. In order to improve the ability of employees to respond quickly to emergencies such as power outages and overall linkage, the pharmaceutical company organized relevant personnel to conduct this self-provided generator set power generation and transmission drill.
In order to ensure the safe and orderly conduct of this exercise, the pharmaceutical company carefully prepared the exercise plan and conducted a comprehensive inspection and maintenance of all wires, cables, machinery and equipment. Yuan Jie, secretary of the general party branch, and Jiang Xiaohua, director of quality, supervised and commanded the drill site. The security personnel, electricians, computer room maintainers, warehouse managers, refrigeration equipment operators and other corresponding personnel of the pharmaceutical company were in place one by one. At the same time, Jinhua Power Supply Bureau 110 power repair experts were also invited to give on-site operation guidance. At about 2
, 110 electric emergency repair personnel enter the high-voltage power distribution room to cut off the mains power supply, switch the mains power / generator device, and make corresponding settings. The electrician of the pharmaceutical company starts the diesel generator set, adjusts the output current and voltage, switches on the grid with the high-voltage transformer for power supply, and notifies the warehouse refrigeration equipment operator to turn on the refrigeration fan, after a period of operation, the voltage and current display are normal, the machine runs normally, and the indoor temperature display drops. The drill is a complete success.
This exercise is an important measure in response to the "Safety Education Year" activities of the group company. It has accumulated practical experience and strengthened the cooperation between various departments under emergency conditions, which is safe and stable for the pharmaceutical company. Lay a solid foundation for development. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31